(AGIO) Agios Pharm - Ratings and Ratios

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies targeting cellular metabolism. Its lead product, PYRUKYND (mitapivat), is a pyruvate kinase activator approved for adults with pyruvate kinase deficiency, a rare hemolytic anemia. The drug is also in Phase 3 trials for sickle cell disease and is being evaluated for pediatric PK deficiency and thalassemia in both transfusion-dependent and non-transfusion-dependent patients. Beyond PYRUKYND, Agios is advancing tebapivat, another PK activator, for lower-risk myelodysplastic syndrome and hemolytic anemias. Its pipeline also includes AG-181, a phenylalanine hydroxylase stabilizer for phenylketonuria, and AG-236, an siRNA targeting TMPRSS6 for polycythemia vera. Founded in 2007 and based in Cambridge, Massachusetts, Agios has established itself as a leader in metabolic disorders. Web URL: https://www.agios.com

Based on the provided data, Agios Pharmaceuticals (NASDAQ:AGIO) is currently trading at $29.69 with a market cap of $1.697 billion. The stock has shown volatility, with its SMA 20 at $27.58 and SMA 50 at $30.49, indicating recent upward momentum. The ATR of 1.59 suggests moderate price movement. Fundamental analysis highlights a P/E ratio of 2.54 and a forward P/E of 2.47, signaling undervaluation relative to earnings expectations. The P/B ratio of 1.10 reflects a reasonable valuation relative to book value, while the P/S ratio of 46.50 indicates a premium based on sales. The RoE of 43.72% underscores strong profitability relative to equity.

3-month forecast: Technical indicators suggest AGIO may test resistance near $32 (SMA 50) with support at $27 (SMA 20). The ATR of 1.59 implies potential price swings of $1.20-$1.90 over the next quarter. Fundamental momentum could drive upward movement if Phase 3 trials for sickle cell disease show positive results. However, market sentiment and broader biotech sector trends will also influence price action. Target range: $27-$35.